Most clinicians no longer need to be persuaded that artificial intelligence belongs somewhere in the conversation about modern practice. What they need is a way to separate a polished demonstration from a tool that will still be useful at 4:30 p.m. on a Friday, when the waiting room is full and a question about antibiotic duration needs an answer in under a minute. Vendor presentations tend to emphasise the same handful of themes — speed, convenience, a friendly interface — while the criteria that genuinely matter to physicians are quieter and more practical: whether an answer can be traced to a source, what happens to the clinical details typed into a query box, and whether the tool fits the shape of an EHR-centred day rather than sitting off to the side of it.
Shortlisting is therefore less about ranking features than about applying a consistent set of filters to every candidate. The three described below are the ones that recur most often in conversations among hospitalists, family physicians, primary care teams, pharmacists, and residents evaluating clinical decision support. None of them replace clinical judgment. AI supports decisions; the clinician still verifies every answer against the cited primary source before acting on it.
Evidence Quality and Citation Transparency
The first question most physicians ask is not “how fast is it?” but “where did that come from?” An AI answer that cannot be traced is, clinically speaking, an unsourced opinion delivered with confidence — and confidence is not evidence. Citation transparency is the single most useful discriminator in a market where many tools can produce fluent prose but far fewer can point to the journal article, systematic review, or guideline that supports each claim.
In practice, good citation behaviour has recognisable markers. A citation should name the source specifically enough to be findable — title, journal or issuing body, and publication or revision date — and should link directly to the material rather than to a landing page or a general topic overview. Ideally the tool shows the relevant passage or abstract so the clinician can judge context without abandoning the question. Just as important is how a tool behaves when evidence is thin, conflicting, or absent: the strongest platforms say so plainly rather than smoothing over uncertainty with plausible-sounding text. Pay attention, too, to whether the tool distinguishes between types of evidence. A society guideline, a randomised trial, and an expert commentary carry different weight, and a system that blurs them is harder to trust.
A practical shortlisting exercise is to build a small question set before trialling anything. Choose ten to fifteen questions from your own practice with answers you already know, then deliberately include one obscure scenario and one where guidance has recently changed. Watch whether the tool surfaces the updated recommendation or an outdated one, and whether it declines to answer rather than inventing a source. Teams comparing the best medical AI tools for doctors usually find this single test more informative than any feature matrix, because it reveals how a system behaves under the conditions clinicians actually work in. When competing bodies disagree — a screening interval, for instance, where a national task force and a specialty society differ — a useful tool presents both positions with their sources instead of averaging them into a single tidy recommendation that belongs to neither.
Privacy, HIPAA Considerations, and the Text You Type In
The query box is where most privacy risk enters a practice, and it enters quietly. Clinicians are trained to think in specifics, and specifics are exactly what should not be typed into a system that has not been reviewed. Before a tool reaches a shortlist, the conversation about data handling should happen earlier and in more detail than the conversation about features. That means asking directly whether queries are retained, for how long, and by whom they can be reviewed; whether submitted text is used to train or improve models; where processing takes place; and what documentation the vendor can supply for a privacy officer to assess. This article cannot confirm the compliance posture of any product, and clinicians should be sceptical of anyone who offers assurances without paperwork.
HIPAA considerations are not abstract. Questions worth putting to a vendor include whether a business associate agreement is available when protected health information may be involved, whether audit logs exist, what happens to data if the practice ends the relationship, and how the tool behaves on personal mobile devices used at the bedside. Voice input deserves particular scrutiny, since spoken queries can capture identifiers that typed ones avoid. Institutional policy matters as much as vendor policy: many health systems maintain an approved-software list, and a well-liked tool that sits outside it creates shadow IT rather than efficiency. Involving the privacy or compliance office during evaluation — not after a pilot — saves considerable rework.
There is also a practical middle path that many teams adopt while evaluating. Deliberately phrase questions without identifiers: describe a patient by clinical features rather than name, date of birth, or room number, and apply the minimum-necessary principle even when the tool seems low risk. Run the first weeks of any pilot on non-PHI questions only. A related question is documentation — if an AI-assisted answer informs a decision, does the reasoning belong in the chart, and in what form? Answering that before rollout prevents inconsistency between clinicians later on.
Workflow Fit, Team Usability, and the Cost of a Click
Clinical tools succeed or fail on friction. A platform that produces an excellent answer in ninety seconds is useless if the question needed answering in fifteen, and a system requiring three window switches, a login, and a rephrased query will be abandoned by the second week. When shortlisting, measure the real path: how many actions from question to sourced answer, how the tool behaves on the device already in the clinician’s hand, and whether it works acceptably on a tablet or phone during rounds. EHR-centred workflows raise a specific question here — does using the tool mean leaving the chart, and how often? Tools designed for natural-language questions, typed or spoken, with answers linked to peer-reviewed sources and guidelines, tend to fit better than those requiring search syntax or query construction, simply because clinicians ask questions in sentences. ZoeMD, for example, is built around that pattern and is available across desktop, tablet, and mobile — a description that should immediately prompt the follow-up question of whether it suits your team at its busiest hour.
Team breadth is the criterion most often overlooked. A tool shortlisted by one enthusiastic physician may not serve the pharmacist checking an interaction, the advanced practice provider covering an evening shift, or the nurse practitioner in a satellite clinic. Ask whether the tool answers consistently across users and phrasings, whether the reading level and output format suit different roles, and how much training adoption actually requires. A system that needs a lunchtime tutorial for every new rotation is a system that will be used inconsistently. It is also worth asking who owns the tool internally after purchase — someone has to review updates, gather feedback, and decide when a subscription no longer earns its place.
Finally, structure the trial deliberately rather than letting a free period drift. Two to four weeks with a defined small group, a shared log of questions asked and whether the tool changed anything about the plan, and a review of cost and exit terms alongside performance will produce a far more reliable decision than impressions gathered from a vendor demonstration. The clinicians who shortlist well are the ones who treat evaluation as a clinical exercise in its own right: defined question, expected answer, verification against the source.
A Gothenburg marine-ecology graduate turned Edinburgh-based science communicator, Sofia thrives on translating dense research into bite-sized, emoji-friendly explainers. One week she’s live-tweeting COP climate talks; the next she’s reviewing VR fitness apps. She unwinds by composing synthwave tracks and rescuing houseplants on Facebook Marketplace.